Yahoo Finance

GSK Reworks Liver Portfolio As Linerixibat Deal Raises Valuation Questions

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. GSK (LSE:GSK) has licensed worldwide rights to its experimental liver disease drug ...

35Pharma to be Acquired by GSK to Accelerate Development of HS235, a Potential Best-in-Class Investigational Medicine for Pulmonary Hypertension (PH)

Acquisition includes HS235, a potentially best-in-class activin signalling inhibitor in clinical development for treatment of cardiopulmonary ...
Morningstar

Hengrui Pharma Signs Milestone Drug-Development Deal With GSK

Chinese drugmaker Jiangsu Hengrui Pharmaceuticals has agreed to develop up to 12 of its drugs with British pharmaceutical giant GSK. Hengrui Pharma granted GSK an exclusive worldwide licence to its ...

Frontier Biotech and GSK Enter Global Exclusive Licensing Agreement for Small Interfering RNA Therapeutics

"We are excited to establish the agreement with GSK, a global biopharma company. It reflects the growing recognition of our R&D capabilities. This agreement will solidify a robust foundation for ...

GSK RAPT Acquisition Adds Food Allergy Asset To Immunology Growth Story

GSK (LSE:GSK) has completed its acquisition of RAPT Therapeutics, securing global rights to key immunology assets. The deal brings ozureprubart, a monoclonal antibody for severe food allergies, into ...

GSK to buy 35Pharma for $950 million in CEO Miel's second major deal

Feb 25 (Reuters) - GSK has agreed to pay $950 million in cash for Canadian biotech 35Pharma, it said on Wednesday, marking ...
Nasdaq

iTeos Therapeutics and GSK announce development and commercialisation collaboration for EOS-448, an anti-TIGIT monoclonal antibody, enabling novel next-generation immuno ...

GOSSELIES, Belgium and LONDON, June 14, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics (NASD: ITOS) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced an agreement to co-develop and co-commercialise ...